Proteostasis Therapeutics Announces Global License Agreement with Genentech

Agreement Covers Small Molecule Modulators of the Cellular Proteostasis Network BOSTON, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to th... Biopharmaceuticals, Licensing Proteostasis Therapeutics, Genentech, Roche Group
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news